News Briefs

It's called "pay for delay": One prescription drug company pays another to keep a generic drug out of the marketplace. And it's costing us, as consumers and taxpayers, an estimated $3.5 billion each year.

A bill in the California Assembly, however, could prevent drug manufacturers from cutting pay-for-delay deals. On Aug. 30, lawmakers, patients and healthcare advocates joined CALPIRG at the State Capitol to rally in support of the bill.

CALPIRG's analysis of the top 20 drugs impacted by pay-for-delay deals reveals that the agreements have delayed generic medicines by an average of five years, forcing patients to buy brand-name equivalents with costs 10 times as high. “It’s outrageous that drug companies get away with making sweetheart deals to keep lower-priced generic medicine off the market,” said CALPIRG Executive Director Emily Rusch to The Los Angeles Times.

The California bill is co-sponsored by Assemblymember Jim Wood and Attorney General Xavier Becerra.

Photo: CALPIRG Executive Director Emily Rusch speaks in support of a bill that would prevent drug companies from striking pay-for-delay deals. Credit: Staff 

Support Us

Your donation supports CALPIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code

Thank you.

We are grateful for all the Giving Tuesday support. 
You can still donate and stand together with us.

CALPIRG is part of The Public Interest Network, which operates and supports organizations committed to a shared vision of a better world and a strategic approach to getting things done.